Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.
Ampath will be one of the first laboratories in South Africa to offer a CE-IVD accredited noninvasive prenatal testing center and will act as a hub for such services.
Illumina has filed a new lawsuit against Premaitha, claiming it infringes on an Illumina patent related to noninvasive prenatal testing.
Premaitha will issue Thermo Fisher warrants over 28,938,797 new ordinary shares and a second tranche of warrants in 2018.
For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
The firm has seen a small handful of false positives for the test in thousands of samples run since the study, but attributed them to biological features.
The company said that Illumina and Sequenom's NIPT patents are not present in the Middle East, allowing it to sell its Iona test unimpeded.
The acquisition will expand Premaitha's market in Asia, enable it to develop new products, and strengthen its patent position in NIPT.
A hospital lab associated with Mahidol University in Thailand will now offer the firm's Iona test in that country and its neighbors.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.